首页> 美国卫生研究院文献>British Journal of Cancer >SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting

【2h】

SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting

机译：SELECT-3：selumetinib联合铂-双线化疗在一线治疗中晚期NSCLC的I期研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: We investigated selumetinib (AZD6244, ARRY-142886), an oral, potent, and highly selective, allosteric MEK1/2 inhibitor, plus platinum-doublet chemotherapy for patients with advanced/metastatic non-small cell lung cancer.

机译：背景：我们研究了selumetinib（AZD6244，ARRY-142886），这是一种口服，有效，高度选择性的变构MEK1 / 2抑制剂，联合铂-双重化疗用于晚期/转移性非小细胞肺癌患者。

著录项

期刊名称 British Journal of Cancer
作者
Alastair Greystoke; Nicola Steele; Hendrik-Tobias Arkenau; Fiona Blackhall; Noor Md Haris; Colin R Lindsay; Raffaele Califano; Mark Voskoboynik; Yvonne Summers; Karen So; Dana Ghiorghiu; Angela W Dymond; Stuart Hossack; Ruth Plummer; Emma Dean;
展开▼
作者单位

展开▼
年(卷),期 2017(117),7
年度 2017
页码 938–946
总页数 9
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
selumetinib MEK1/2 inhibitor non-small cell lung cancer chemotherapy;

机译：selumetinib;MEK1 / 2抑制剂;非小细胞肺癌;化学疗法;

相似文献

外文文献
中文文献
专利

1. SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting [J] . AlastairGreystoke, NicolaSteele, Hendrik-TobiasArkenau, British Journal of Cancer . 2017,第7期

机译：SELECT-3：selumetinib联合铂双药化疗在一线治疗中晚期NSCLC的I期研究
2. Efficacy and Safety Results From a Phase 2, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy in Advanced Squamous-Cell Non-Small Cell Lung Cancer (sq NSCLC) [J] . Hirsch F. R., Govindan R., Zvirbule Z., International Journal of Radiation Oncology, Biology, Physics . 2014,第5Suppla期

机译：来自Onartuzumab联合一线铂-双线化疗在晚期鳞状细胞非小细胞肺癌（sq NSCLC）的第2期安慰剂对照研究中的疗效和安全性结果
3. AvaALL: Open-Label Randomized Phase 1Mb Trial Evaluating the Efficacy and Safety of Standard of Care With or Without Continuous Bevacizumab (BV) Treatment Beyond Disease Progression in Patients (pts) With Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) After First-Line (1L) Treatment With BV Plus Platinum-Doublet Chemotherapy (CT) [J] . Clinical advances in hematology & oncology: H&O . 2012,第Suppla11期

机译：AvaALL：开放标签随机1Mb临床试验，评估在初次手术后晚期非鳞状非小细胞肺癌（NSCLC）患者病情进展之外，是否进行持续贝伐单抗（BV）治疗的标准治疗的有效性和安全性BV加上铂金双线化疗（CT）的线（1L）治疗
4. Radio-Thermo-chemotherapy Comprehensive Treatment Advanced NSCLC [C] . The 3rd Asian congress on hyperthermic oncology and the 9th Chineses symposium on hyperthermic oncology . 2002

机译：放化疗综合治疗晚期非小细胞肺癌
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. Phase III randomized open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC [O] . Naiyer Rizvi, Fabrice Barlesi, Julie Brahmer, 2015

机译：晚期转移性NSCLC患者一线治疗中的durvalumab（MEDI4736）联合tremelimumab或durvalumab单独与铂类化疗联合进行的III期随机开放标签研究：MYSTIC
7. SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting. [O] . Greystoke, A, Steele, N, Arkenau, HT, 2017

机译：sELECT-3：selumetinib与铂 - 双联化疗相结合的I期研究，用于晚期NsCLC的一线治疗。

SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting

摘要

著录项

相似文献

相关主题

期刊订阅